EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
出版年份 2012 全文链接
标题
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 131, Issue 12, Pages 2961-2969
出版商
Wiley
发表日期
2012-04-19
DOI
10.1002/ijc.27604
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Selection of Patients with Hepatocellular Carcinoma for Sorafenib
- (2017) Ghassan K. Abou-Alfa Journal of the National Comprehensive Cancer Network
- Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study
- (2011) C. Gridelli et al. ANNALS OF ONCOLOGY
- Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
- (2011) J. P. Arnault et al. CLINICAL CANCER RESEARCH
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Hepatocellular Carcinoma: Novel Molecular Approaches for Diagnosis, Prognosis, and Therapy
- (2010) Augusto Villanueva et al. Annual Review of Medicine
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
- (2010) Sonja J. Heidorn et al. CELL
- Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis
- (2010) Susie A. Lee et al. HEPATOLOGY
- BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma
- (2010) A. Galmiche et al. MOLECULAR CANCER RESEARCH
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC)
- (2009) Hung Huynh et al. JOURNAL OF HEPATOLOGY
- Epidermal Growth Factor Receptor Expression and Gene Copy Number in Conventional Hepatocellular Carcinoma
- (2008) Anne F. Buckley et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation